Vicore to Present at Upcoming Investor Conferences

Stockholm, February 26, 2025 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the following investor conferences: 

  • TD Cowen 45th Annual Health Care Conference 
    Location: Boston, USA 
    Format: Presentation and 1x1 meetings 
    Presentation Date and Time: Tuesday, March 4 at 11:50 AM ET/5:50 PM CET 
    Webcast: https://wsw.com/webcast/cowen177/vico/2027211 
    Participants: Ahmed Mousa, CEO; Hans Jeppsson, CFO; Megan Richards, VP of IR 
     
  • Leerink Partners Global Healthcare Conference 2025 
    Location: Miami, USA 
    Format: Presentation and 1x1 meetings 
    Presentation Date and Time: Tuesday, March 11 at 1:00 PM ET/7:00 PM CET 
    Webcast: https://wsw.com/webcast/leerink38/vico/2226949 
    Participants: Ahmed Mousa, CEO; Megan Richards, VP of IR 
     
  • 28th Annual Carnegie Nordic Healthcare Seminar  
    Location: Stockholm, Sweden
    Format: Presentation and 1x1 meetings 
    Presentation Date and Time: Wednesday, March 12 at 7:00 AM ET/1:00 PM CET 
    Participants: Ahmed Mousa, CEO; Hans Jeppsson, CFO 

Interested parties may also access the webcast replay on the Events & Presentations page of Vicore’s website for 90 days following the conclusion of the event.
 
For further information, please contact: 
Megan Richards, VP of IR, Communications, and Portfolio Strategy, tel: +1 978 269-4372, megan.richards@vicorepharma.com    
Hans Jeppsson, CFO, tel: +46 70 553 14 65, hans.jeppsson@vicorepharma.com 

About Vicore Pharma 
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company’s lead program, buloxibutid (C21), is a first-in-class oral small molecule angiotensin II type 2 (AT2) receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA) and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. 

The company is publicly listed on the Nasdaq Stockholm exchange (VICO). www.vicorepharma.com 

Datum 2025-02-26, kl 08:00
Källa MFN
Hej Serverägare! Har du problem med troll och spam? Nu finns möjligheten att sätta en liten avgift, t.ex. 20kr, på discord invites och därmed stoppa många återkommande troll samtidigt som du tjänar lite pengar. Kolla in Invite Paywall.